| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner | Director
6 companies
Beth C Seidenberg is Director, 10% Owner at LTGO and has filed Form 4s across 6 companies. Beth C Seidenberg's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $37.4M at current prices.
Historically, Beth C Seidenberg's trades have earned a strong insider score of 75/100 across 25 rated trades. Over a 12-month horizon, 95.8% of those trades were profitable, with an average 12-month return of +81.2%.
The biggest single holding is LTGO (~$30.5M) as Director, 10% Owner.
Beth C Seidenberg has 66 Form 4 filings on record from May 2015 to August 2026, across 6 companies: Director, 10% Owner at Latigo Biotherapeutics (LTGO), 2026; Director at Sagimet Biosciences (SGMT), 2023–2026; Director at Kyverna Therapeutics (KYTX), 2024–2026, and 3 more.
The 163 reported transactions were 57 other transactions, 31 option or other derivative awards, 22 open-market purchases and 16 conversions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 15 purchases worth about $7.1M and 6 sales worth about $5.2M.
The largest open-market purchase was 311,078 shares of VERA at an average $7.10 on February 8, 2023, about $2.2M. Twelve months later VERA was up 419%.
The largest open-market sale was 38,461 shares of PGNY at an average $42.00 on December 14, 2020, about $1.6M.
Both sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 18, 2025 | KYTX Kyverna Therapeutics, Inc. | Director | Buy | 133,333 | $7.50 | $999,997.50 | +18.1% | +22.0% | - | |
| Oct 28, 2024 | VERA Vera Therapeutics, Inc. | Director | Sell10b5-1 | 15,000 | $48.03 | $720,493.22 | -10.2% | -26.4% | -36.7% | |
| Sep 19, 2024 | VERA Vera Therapeutics, Inc. | Director | Sell10b5-1 | 16,476 | $42.26 | $696,233.08 | -10.1% | -1.5% | -39.1% | |
| Jul 18, 2023 | SGMT Sagimet Biosciences Inc. | Director | Buy | 46,875 | $16.00 | $750,000.00 | New | -63.0% | -78.7% | |
| Mar 30, 2023 | VERA Vera Therapeutics, Inc. | Director | Buy | 2,300 | $7.24 | $16,650.85 | +0.1% | +139.7% | +479.6% | |
| Mar 28, 2023 | VERA Vera Therapeutics, Inc. | Director | Buy | 23,908 | $7.24 | $173,191.94 | +1.2% | +140.8% | +503.7% | |
| Mar 27, 2023 | VERA Vera Therapeutics, Inc. | Director | Buy | 3,466 | $7.24 | $25,102.11 | +0.2% | +139.5% | +469.6% | |
| Mar 20, 2023 | VERA Vera Therapeutics, Inc. | Director | Buy | 89,297 | $7.13 | $636,914.51 | +4.9% | +101.2% | +480.5% | |
| Mar 16, 2023 | VERA Vera Therapeutics, Inc. | Director | Buy | 92,941 | $7.10 | $660,278.24 | +5.3% | +83.9% | +495.7% | |
| Mar 10, 2023 | VERA Vera Therapeutics, Inc. | Director | Buy | 48,003 | $7.16 | $343,485.47 | +2.8% | +18.0% | +501.1% |